Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Eliyahu, Efrat ^a   Wolfson, Theodore ^a   Ge, Yi ^a   Jepsen, Karl J ^a   Schuchman, Edward H ^a   Simonaro, Calogera M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CERAMIDE; CNTO 1081; COLLAGEN TYPE 2; GALSULFASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE; BONE GROWTH; BONE STRUCTURE; CARTILAGE CELL; CELL CULTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME REPLACEMENT; GROWTH PLATE; MAROTEAUX LAMY SYNDROME; MOTOR ACTIVITY; NONHUMAN; PHYSICAL MOBILITY; PROTEIN EXPRESSION; RAT; TRACHEA DISEASE; TREATMENT OUTCOME; ANIMAL; CONGENITAL MALFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GAIT; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; TRACHEA;

ANIMALIA; RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE AND BONES; CARTILAGE, ARTICULAR; CHONDROCYTES; ENZYME REPLACEMENT THERAPY; GAIT; HUMANS; MOTOR ACTIVITY; MUCOPOLYSACCHARIDOSIS VI; RATS; TRACHEA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051940065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022447     Document Type: Article

References (32)

1. Neufeld EF, Meunzer J, (2001) The Mucopolysaccharidoses. Metabolic and Molecular Basis of Inherited Disease pp. 3421-3452.
2. Clarke LA, (2008) The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med 10: e1.
3. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, et al. (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167: 267-77.
4. Cox-Brinkman J, van den Bergh Weerman MA, Wijburg FA, Aerts JM, Florquin S, et al. (2010) Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: Effects of enzyme replacement therapy and hematopoietic cell transplantation. Ultrastruct Pathol 34: 126-32.
5. Coppa GV, Buzzega D, Zampini L, Maccari F, Galeazzi T, et al. (2010) Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients. Glycobiology 20: 1259-73.
6. Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, et al. (2011) Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis Feb 16 [Epub ahead of print].
7. Decker C, Yu ZF, Giugliani R, Schwartz IV, Guffon N, et al. (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3: 89-100.
8. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S, (2010) Mucopolysaccharidosis VI. Orphanet J Rare Dis 12: 5.
9. McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, et al. (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 77: 492-498.
10. Cotugno G, Tessitore A, Capalbo A, Annunziata P, Strisciuglio C, et al. (2010) Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther 21: 555-69.
11. Herati RS, Knox VW, O'Donnell P, D'Angelo M, Haskins ME, et al. (2008) Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol Genet Metab 95: 142-51.
12. Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM, (2011) Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng Feb 23 [Epub ahead of print].
13. Osborn MJ, McElmurry RT, Lees CJ, Defeo AP, Chen ZY, et al. (2011) Minicircle DNA-based Gene Therapy Coupled With Immune Modulation Permits Long-term Expression of α-L-Iduronidase in Mice With Mucopolysaccharidosis Type I. Mol Ther 19: 450-60.
14. Simonaro CM, Haskins ME, Kunieda T, Evans SM, Visser JW, et al. (1997) Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings. Transplantation 63: 1386-93.
15. Simonaro CM, Haskins ME, Schuchman EH, (2001) Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Investi 81: 1319-1328.
16. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH, (2005) Joint and bone disease in mucopolysaccharidosis VI and VII: Identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57: 701-707.
17. Simonaro CM, Eliyahu E, Shtraizent N, Haskins ME, Schuchman EH, (2008) Mechanism of glycosaminoglycan-mediated bone & joint disease: Implications for the mucopolysaccharidoses & other connective tissue diseases. Amer J Path 172: 112-122.
18. Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, et al. (2010) Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci 107: 222-7.
19. Weaver AL, (2004) Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol 14: 101-112.
20. Yoshida M, Noguchi J, Ikadai H, Takahashi M, Nagase S, (1993) Arylsulfatase B-deficient mucopolysaccharidosis in rats. J Clin Invest 91: 1099-1104.
21. Kunieda T, Simonaro CM, Yoshida M, Ikadai H, Levan G, et al. (1995) Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics 29: 582-587.
22. Cotugno G, Tessitore A, Capalbo A, Annunziata P, Strisciuglio C, et al. (2010) Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther 21: 555-69.
23. Semenza GL, Pyeritz RE, (1988) Respiratory complications of mucopolysaccharide storage disorders. Medicine 67: 209-19.
24. Becker KA, Tümmler B, Gulbins E, Grassmé H, (2010) Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem Biophys Res Commun 17: 368-74.
25. Metcalf JA, Zhang Y, Hilton MJ, Long F, Ponder KP, (2009) Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 97: 202-211.
26. Miebach E, (2005) Enzyme replacement therapy in mucopolysaccharidosis type I. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. Acta Paediatr Suppl 94: 58-60.
27. Auclair D, Hopwood JJ, Lemontt JF, Chen L, Byers S, (2007) Long-term intra-articular administration of recombinant human N-acetylgalactosamine 4-sulfatase in feline mucopolysaccharidosis VI. Mol Gen Metab 91: 352.
28. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP, (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63: 359-64.
29. Rodgers M, Epstein D, Bojke L, Yang H, Craig D, et al. (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 15: 1-329.
30. Rutella S, Fiorino G, Vetrano S, Correale C, Spinelli A, et al. (2011) Infliximab Therapy Inhibits Inflammation-Induced Angiogenesis in the Mucosa of Patients With Crohn's Disease. Am J Gastroenterol Mar 1 [Epub ahead of print].
31. Connor V, (2011) Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int 31: 327-37.
32. Shinhar SY, Zablocki H, Madgy DN, (2004) Airway management in mucopolysaccharide storage disorders. Arch Otolaryngol Head Neck Surg 130: 233-237.